GeneDx Holdings Corp. - Class A Common Stock (WGS)

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and intellectual disability (DD/ID). The data was unveiled today at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting in Baltimore, MD.

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx’s industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diagnoses faster and guide clinical decision-making. De-identified data from the program will be added to GeneDx Infinity™, the largest and most comprehensive rare disease dataset, to help drive faster diagnoses of NPC to help patients and providers make informed treatment decisions.

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two rapid fire poster talks, with research spanning sequencing innovations, breakthroughs in AI-supported interpretation, novel gene-disease discoveries, the real-world impact of earlier diagnoses, and more.

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:

Insert the "Software and interpretation services" row in the Volume & Revenue(1) table.

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its President and Chief Executive Officer Katherine Stueland has been named to the TIME100 Health 2026 list – TIME’s annual recognition of the 100 individuals who most influenced global health over the past year.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026. Management will host a conference call that day to discuss fourth quarter 2025 financial and operating results at 8:30 a.m. Eastern Time.

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2025.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, the leader in AI-powered healthcare intelligence. Through the partnership, GeneDx’s Infinity™ will leverage real-world patient insights from Komodo’s Healthcare Map®, to create the most comprehensive, longitudinal dataset for rare disease. The collaboration will unlock a new level of visibility into how rare diseases are diagnosed, managed, and treated across the full patient journey.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GenomeDx Prenatal™, whole genome sequencing (WGS) designed to deliver clear, reliable answers during one of the most critical moments in pregnancy care. The phenotype-informed, trio-based test is intended for pregnancies with fetal anomalies identified via ultrasound, enabling clinicians and expecting families to access actionable genomic insights with a rapid turnaround time. In contrast to carrier or noninvasive prenatal screening that identifies pregnancies at risk of having a genetic disorder, prenatal diagnostic testing can determine whether a pregnancy is affected by a genetic disorder.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company’s commitment to delivering earlier answers and better outcomes for families through genomic insights.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a record-setting year for its Medical Affairs and research programs, reinforcing its position as the global leader in rare disease genomics. In 2025, GeneDx published 79 peer-reviewed studies bringing its total to over 1,100 peer-reviewed studies – all powered by GeneDx Infinity™ – delivering the most prolific and clinically impactful research portfolios in rare disease genomics.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15 in San Francisco, CA. Katherine Stueland, President and Chief Executive Officer, will participate in a presentation on Wednesday, January 14, 2026, at 3:00 p.m. PT.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns) study has been recognized as part of JAMA’s annual Research of the Year Roundup. This highly selective honor is reserved for the most impactful scientific contributions published across all JAMA journals.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2025.

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced data and presentations at the International Consortium on Newborn Sequencing (ICoNS), underscoring the company’s leadership in driving genomic newborn screening (gNBS) from research into real-world clinical implementation.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its whole genome and exome tests associated with causes of life-threatening diseases or genetic disorders to aid in diagnosis of symptomatic patients.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer. Dr. Lee will spearhead GeneDx’s vision to unlock the power of genomics to help every person live their healthiest life.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Florida State University has selected GeneDx as one of its partners for the recently passed Sunshine Genetics Act, a groundbreaking initiative establishing the nation’s first state-backed genomic newborn screening (gNBS) program.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the Autism Partnership Program to expand access to its industry leading exome and genome testing – the only autism testing program committed to delivering answers to families in weeks. Jaguar Gene Therapy joins the program as the founding partner, initiating a genetic testing program for individuals clinically suspected of having SHANK3-related autism spectrum disorder (ASD) and Phelan-McDermid syndrome. A single pathogenic variant or deletion in the SHANK3 gene is a leading single-gene cause of ASD.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced pioneering scientific contributions that will be presented at the American Society of Human Genetics (ASHG) Annual Meeting.